Immunotherapy plus chemo shows promise for rare bladder cancers

NCT ID NCT04383743

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study tested whether giving pembrolizumab (an immunotherapy) along with standard chemotherapy before surgery could help people with rare types of muscle-invasive bladder cancer. 17 participants received the combination, and researchers measured how many had no cancer left at the time of surgery. The goal is to see if this approach works better than chemotherapy alone for these less common bladder cancer variants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pembrolizumab (immunotherapy) and cisplatin-based chemotherapy
What this could lead to
If successful, this approach could improve the chance of eliminating all cancer before surgery for people with rare bladder cancer types.
What could go wrong
This is a very small pilot study with only 17 participants, so results may not apply to everyone. The combination also carries risks of side effects from both immunotherapy and chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.